vimarsana.com

Latest Breaking News On - Candice long - Page 1 : vimarsana.com

Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis

The Company1 enters agreement with Numab Therapeutics to acquire its wholly owned subsidiary2 for the global rights to NM26, a Phase 2-ready investigational, first-in-class bispecific antibody.

David leeNone of cilag holdingJanssen research developmentJanssen biotech incCilag holdingNumab therapeuticsGlobal immunology therapeutic area headJohnson innovativeCandice longWorldwide vice presidentHart scott rodino antitrust improvements actInnovative medicineJanssen researchJanssen biotechAnnual reportNote regarding forward looking

J&J gains another bispecific antibody with $1 25B skin drug buy

BioPharma

Abbvie rinvoqRegeneron dupixentAmbrx biopharmaNovo holdingsBoehringer ingelheimDive briefYellow jersey therapeuticsCandice long

J&J scoops up another atopic dermatitis drug for $1 25B

J&J scoops up another atopic dermatitis drug for $1 25B
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Michael bauerNovo holdingsNovo holdings partnerNumab therapeuticYellow jersey therapeuticsYellow jerseyHoldings partnerCandice long

J&J: towards acquisition of Proteologix for $850 million

J&J: towards acquisition of Proteologix for $850 million
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Integrating proteologixCandice longGlobal vice president

J&J acquires Proteologix for $850M, adds bispecific antibodies to pipeline

The Proteologix deal marks the second big pharma buy for J&J in 2024, following its acquisition of Amrbx Biopharma earlier this year.

Ambrx biopharmaDavid leeCandice long

vimarsana © 2020. All Rights Reserved.